Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Boston-based Bicara launched in 2021 and is a subsidiary of Indian pharma company Biocon, which provided its seed funding. Bicara is also studying ficerafusp alfa, its lead candidate, in anal cancer ...

A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...

Survivors of blood or marrow transplants (BMT) face a significantly higher risk of developing cutaneous malignant neoplasms, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...

CORONADO, Calif. — Despite recent advances in the treatment of cutaneous squamous cell carcinoma (SCC), a lack of consensus ...

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

Nearly two months after Randy Moss underwent surgery following his cancer diagnosis, the ESPN commentator made an appearance virtually at the 2025 NFL Honors to present an award.

Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Merus (MRUS) with an Overweight rating and $91 price target The firm thinks ...

More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, ...